fluorodopa f 18 has been researched along with Movement Disorders in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marek, K; Poewe, W; Scherfler, C; Tolosa, E | 1 |
| Seibyl, JP | 1 |
| Gorman, JM | 1 |
| Chen, W; Seibyl, JP; Silverman, DH | 1 |
| Cesaro, P; Defer, GL; Degos, JD; Fenelon, G; Gaston, A; Geny, C; Jeny, R; Keravel, Y; Monfort, JC; Nguyen, JP; Peschanski, M; Remy, P; Ricolfi, F; Samson, Y; Villafane, G | 1 |
| Fukumura, T; Hosokawa, S; Ichiya, Y; Kato, M; Kuwabara, Y; Masuda, K; Otsuka, M; Sasaki, M; Yoshida, T | 1 |
| Bergman, J; Haaparanta, M; Hublin, C; Partinen, M; Rinne, JO; Ruottinen, HM; Solin, O | 1 |
| Calne, DB; de la Fuente-Fernández, R; Kishore, A; Mak, EK; Pal, PK; Ruth, TJ; Schulzer, M; Snow, BJ; Stoessl, AJ; Vingerhoets, FJ | 1 |
2 review(s) available for fluorodopa f 18 and Movement Disorders
| Article | Year |
|---|---|
Imaging studies in movement disorders.
Topics: Brain; Cocaine; Dihydroxyphenylalanine; Dopamine; Humans; Movement Disorders; Parkinson Disease; Predictive Value of Tests; Radiopharmaceuticals; Severity of Illness Index; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2003 |
3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors.
Topics: Adrenal Gland Neoplasms; Amino Acids; Brain Neoplasms; Caudate Nucleus; Dihydroxyphenylalanine; Fluorine Radioisotopes; Glioma; Humans; Movement Disorders; Neuroendocrine Tumors; Parkinsonian Disorders; Positron-Emission Tomography; Putamen; Radiopharmaceuticals | 2007 |
6 other study(ies) available for fluorodopa f 18 and Movement Disorders
| Article | Year |
|---|---|
Supplement neuroimaging movement disorders.
Topics: Diagnostic Imaging; Dihydroxyphenylalanine; Humans; Magnetic Resonance Imaging; Movement Disorders; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2009 |
More to movement disorders than motion.
Topics: Basal Ganglia; Deep Brain Stimulation; Dihydroxyphenylalanine; Humans; Mental Disorders; Movement Disorders; Parkinson Disease; Positron-Emission Tomography | 2006 |
Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach.
Topics: Aged; Antiparkinson Agents; Brain; Brain Tissue Transplantation; Dihydroxyphenylalanine; Female; Fetal Tissue Transplantation; Fluorine Radioisotopes; Follow-Up Studies; Humans; Male; Mesencephalon; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome | 1996 |
Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms.
Topics: Adult; Aged; Caudate Nucleus; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Putamen; Tomography, Emission-Computed; Tremor | 1996 |
An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome.
Topics: Adult; Dihydroxyphenylalanine; Dopamine; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Movement Disorders; Neostriatum; Restless Legs Syndrome; Substantia Nigra; Tomography, Emission-Computed | 2000 |
Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations.
Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Movement Disorders; Parkinson Disease; Presynaptic Terminals; Substantia Nigra; Tomography, Emission-Computed | 2000 |